Appeals court puts the final nail in the coffin for Tecfidera patent, adding to Biogen's burgeoning setbacks
In another setback for Biogen, the big biotech lost its appeal to revive a patent for the once-blockbuster drug Tecfidera, marking a likely conclusion to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
